Metformin: the safest hypoglycaemic agent in chronic kidney disease? - PubMed (original) (raw)

Review

doi: 10.1159/000323739. Epub 2011 Feb 16.

Affiliations

• PMID: 21325870
• DOI: 10.1159/000323739

Free article

Review

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

Helen J Nye et al. Nephron Clin Pract. 2011.

Free article

Abstract

Metformin is the first-line oral agent in the treatment of type 2 diabetes and has many established benefits, including the reduction of macrovascular complications of diabetes. Its prescription in patients with renal impairment is limited by concerns relating to the theoretical risk of lactic acidosis, a fear which is perpetuated by numerous case reports in which it is implicated. Critical review of this literature calls into question the validity of these claims, with metformin usually acting as an 'innocent bystander' in acutely unwell patients with conditions well recognised to precipitate lactic acidosis such as sepsis or hypovolaemia. In fact, the evidence supports the safe use of appropriate doses of metformin in patients with chronic stable renal impairment, and highlights the important possible greater risks of the alternatives, most notably severe hypoglycaemia in patients taking sulphonylureas and/or insulin and fluid retention in patients taking a thiazolidinedione. Other traditional contraindications to metformin use such as heart failure are also being re-evaluated, as the benefits of metformin in these patients are increasingly recognised. Physicians should weigh this evidence carefully before deciding to withdraw metformin therapy in their patients with stable chronic kidney disease.

Copyright © 2011 S. Karger AG, Basel.

PubMed Disclaimer

Similar articles

• Metformin in patients with chronic kidney disease: strengths and weaknesses.
  Rocha A, Almeida M, Santos J, Carvalho A. Rocha A, et al. J Nephrol. 2013 Jan-Feb;26(1):55-60. doi: 10.5301/jn.5000166. J Nephrol. 2013. PMID: 22641582 Review.
• Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment.
  Bruijstens LA, van Luin M, Buscher-Jungerhans PM, Bosch FH. Bruijstens LA, et al. Neth J Med. 2008 May;66(5):185-90. Neth J Med. 2008. PMID: 18490795 Review.
• Metformin-associated lactic acidosis in a low risk patient.
  Ellis AK, Iliescu EA. Ellis AK, et al. Can J Clin Pharmacol. 2001 Summer;8(2):104-6. Can J Clin Pharmacol. 2001. PMID: 11493939 English, French.
• [Metformin-associated lactic acidosis].
  Orban JC, Ghaddab A, Chatti O, Ichai C. Orban JC, et al. Ann Fr Anesth Reanim. 2006 Oct;25(10):1046-52. doi: 10.1016/j.annfar.2006.05.009. Epub 2006 Sep 26. Ann Fr Anesth Reanim. 2006. PMID: 17005358 Review. French.
• [Metformin is also recommended in mild and moderate renal failure].
  Zechmann S. Zechmann S. Praxis (Bern 1994). 2015 Mar 25;104(7):370-1. doi: 10.1024/1661-8157/a001964. Praxis (Bern 1994). 2015. PMID: 25804780 Review. German. No abstract available.

Cited by

• [Diabetic kidney disease (update 2023) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology].
  Sourij H, Edlinger R, Prischl FC, Kaser S, Horn S, Antlanger M, Paulweber B, Aberer F, Brix J, Cejka D, Stingl H, Kautzky-Willer A, Schmaldienst S, Clodi M, Rosenkranz A, Mayer G, Oberbauer R, Säemann M. Sourij H, et al. Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):182-194. doi: 10.1007/s00508-022-02147-3. Epub 2023 Apr 20. Wien Klin Wochenschr. 2023. PMID: 37101040 Free PMC article. German.
• Metformin Suppresses Thioacetamide-Induced Chronic Kidney Disease in Association with the Upregulation of AMPK and Downregulation of Oxidative Stress and Inflammation as Well as Dyslipidemia and Hypertension.
  Alshahrani MY, Ebrahim HA, Alqahtani SM, Bayoumy NM, Kamar SS, ShamsEldeen AM, Haidara MA, Al-Ani B, Albawardi A. Alshahrani MY, et al. Molecules. 2023 Mar 18;28(6):2756. doi: 10.3390/molecules28062756. Molecules. 2023. PMID: 36985728 Free PMC article.
• Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease-A Systematic Review and Meta-Analysis.
  Hu Y, Lei M, Ke G, Huang X, Peng X, Zhong L, Fu P. Hu Y, et al. Front Endocrinol (Lausanne). 2020 Oct 7;11:559446. doi: 10.3389/fendo.2020.559446. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33117278 Free PMC article.
• Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.
  Rhee JJ, Han J, Montez-Rath ME, Kim SH, Cullen MR, Stafford RS, Winkelmayer WC, Chertow GM. Rhee JJ, et al. J Diabetes Complications. 2019 Nov;33(11):107423. doi: 10.1016/j.jdiacomp.2019.107423. Epub 2019 Sep 3. J Diabetes Complications. 2019. PMID: 31537413 Free PMC article.
• [Diabetic kidney disease (Update 2019) : Position paper of the Austrian Diabetes Association and the Austrian Society for Nephrology].
  Sourij H, Edlinger R, Prischl FC, Auinger M, Kaser S, Horn S, Paulweber B, Kautzky-Willer A, Säemann M, Prager R, Clodi M, Schernthaner G, Mayer G, Oberbauer R, Rosenkranz AR. Sourij H, et al. Wien Klin Wochenschr. 2019 May;131(Suppl 1):151-163. doi: 10.1007/s00508-018-1425-x. Wien Klin Wochenschr. 2019. PMID: 30980144 Review. German.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland

• Medical

  • MedlinePlus Health Information